This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Yin Lu
Introduction
Yin Lu is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative compounds aimed at treating various diseases. His work exemplifies the intersection of chemistry and medicine, showcasing the potential of targeted drug design.
Latest Patents
Yin Lu holds a patent for a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring. This invention is particularly important as it provides a new approach to preventing or treating diseases that benefit from the inhibition of capsid protein assembly. The patent highlights the compound's potential applications in drug development, emphasizing its significance in the pharmaceutical industry.
Career Highlights
Yin Lu is associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he continues to advance his research and development efforts. His work has not only contributed to the company's portfolio but has also positioned him as a key player in the field of drug innovation. His dedication to research and development is evident in his successful patent application.
Collaborations
Yin Lu collaborates with talented colleagues, including Meng Guo and Mingtong Hu. These partnerships enhance the research environment and foster innovation within their projects. Working alongside skilled professionals allows for a diverse exchange of ideas and expertise.
Conclusion
Yin Lu's contributions to the field of pharmaceuticals through his innovative patent demonstrate the importance of research and collaboration in advancing medical science. His work continues to inspire future developments in drug design and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile